Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anixa BiosciencesANIX +0.46%31 12-1 Month Momentum % is 4.08% as of Aug. 12, 2026. GuruFocus rates ANIX with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,352 Biotechnology companies, Anixa Biosciences ranks better than 63.02% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-12), Anixa Biosciences's 12-1 Month Momentum % is 4.08%.
The industry rank for Anixa Biosciences's 12-1 Month Momentum % or its related term are showing as below:
ANIX's 12-1 Month Momentum % is ranked better than 63.02% of 1352
companies
in the Biotechnology industry
Industry Median: -14.77
vs ANIX: 4.08
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Anixa Biosciences 12-1 Month Momentum % Related Terms
ANIX vs GUTS, CBUS, GNLX: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Anixa Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (ANIX) has a 12-1 Month Momentum % of 4.08% as of Aug. 12, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #500 out of 1352 companies in the Biotechnology industry, placing it in the top 37%.
Is Anixa Biosciences' 12-1 Month Momentum % too high?
Anixa Biosciences' current 12-1 Month Momentum % is 4.08%. Based on the distribution chart, Anixa Biosciences ranks #500 out of 1352 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' 12-1 Month Momentum % compare to GUTS and CBUS?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #500 out of 1352 companies for 12-1 Month Momentum %. This puts Anixa Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current 12-1 Month Momentum % is 4.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current 12-1 Month Momentum % of 4.08%. The current 12-1 Month Momentum % is 4.08%. Anixa Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current 12-1 Month Momentum % is 4.08% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
31GF Score
Get the complete analysis for ANIX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
